Zhejiang NHU Company Ltd. (SHE:002001)

Verve Therapeutics Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 7, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Market Capitalization	69,674	67,523	52,125	57,627	80,240	72,367
Market Cap Growth	34.25%	29.54%	-9.55%	-28.18%	10.88%	44.80%
Enterprise Value	70,031	70,445	57,895	60,790	81,598	74,978
Last Close Price	22.67	21.29	16.05	17.20	23.13	20.49
PE Ratio	10.11	11.51	19.27	15.92	18.42	20.31
Forward PE	11.68	11.17	13.87	13.53	18.83	15.64
PS Ratio	3.09	3.13	3.45	3.62	5.38	7.02
PB Ratio	2.27	2.29	2.09	2.44	3.67	3.73
P/TBV Ratio	2.47	2.52	2.33	2.64	3.95	4.04
P/FCF Ratio	10.14	12.34	77.35	-	33.93	94.00
P/OCF Ratio	8.51	9.55	10.18	13.21	13.75	23.17
PEG Ratio	3.89	7.89	1.98	1.13	1.68	1.68
EV/Sales Ratio	3.11	3.26	3.83	3.82	5.47	7.27
EV/EBITDA Ratio	6.76	7.61	11.97	11.04	12.91	14.88
EV/EBIT Ratio	8.74	10.00	18.48	14.77	16.00	17.96
EV/FCF Ratio	10.19	12.87	85.92	-	34.50	97.39
Debt / Equity Ratio	0.29	0.30	0.39	0.41	0.39	0.34
Debt / EBITDA Ratio	0.86	0.97	1.99	1.77	1.36	1.29
Debt / FCF Ratio	1.30	1.64	14.29	-	3.63	8.44
Asset Turnover	0.54	0.53	0.39	0.44	0.46	0.35
Inventory Turnover	2.89	3.00	2.45	2.78	2.64	1.79
Quick Ratio	1.95	1.83	1.27	1.20	1.74	1.48
Current Ratio	2.61	2.45	2.02	1.77	2.30	2.12
Return on Equity (ROE)	24.44%	21.69%	11.22%	15.97%	21.17%	19.62%
Return on Assets (ROA)	12.01%	10.72%	5.06%	7.05%	9.71%	8.75%
Return on Capital (ROIC)	13.32%	12.07%	5.76%	8.06%	11.30%	10.27%
Return on Capital Employed (ROCE)	21.70%	19.50%	9.50%	13.60%	18.00%	17.00%
Earnings Yield	9.87%	8.69%	5.19%	6.28%	5.43%	4.92%
FCF Yield	9.86%	8.11%	1.29%	-0.99%	2.95%	1.06%
Dividend Yield	2.23%	2.35%	2.80%	2.91%	2.52%	2.37%
Payout Ratio	32.94%	28.34%	67.80%	58.92%	41.98%	38.60%
Buyback Yield / Dilution	1.66%	1.12%	-0.46%	-0.16%	0.31%	-0.38%
Total Shareholder Return	3.90%	3.47%	2.35%	2.75%	2.83%	1.99%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.